In this meta-analysis, we will assess the overall effect of CYP2C19 POC testing on major cardiovascular events (MACE), including myocardial infarction, stroke, stent thrombosis, or death as well as bleeding associated with clopidogrel therapy. The gene discussed is CYP2C19; the disease is myocardial infarction.